Evaluating the effects of symbiotic therapy in male infertility with idiopathic oligoastenospermia

Evaluation of the therapeutic effect of synbiotics in the treatment of idiopathic oligoastenospermia in men

Blind two-way clinical trial; patients were randomly assigned to two groups of 20 recipients of femoral lactate or placebo by blockchain and would receive their group medication once daily for 4 weeks. Therefore, on a basic basis, demographic and clinical information of registered patients, as well as a serum sample will be taken for the necessary analyzes.

Yazd Reproductive Research Institute

Admission requirements: Age 20 to 50 years, Sperm concentration below 15 million per cc, Percentage of progressive motile spermatozoa < 32%, Total ejaculated spermatozoa<39*106, Total motility <40%, Normal serum levels of free testosterone, Prolactin, Luteinizing hormone, Follicle-stimulating hormone, Conditions for not entering the study: Drug or alcohol abuse, Concentration of white blood cells in semen > 106 per cc, Possibility of being treated with gonadotropins, anabolic steroids, cancer chemotherapy, NSAIDs, infertility medications in the last two months, Previous history of chemotherapy or radiotherapy for cancer, Existence of palpable varicocele, X-ray history of the past eight months, Y chromosome microdeletion, Karyotype alterations, Testicular atrophy and testicular failure, Other secondary causes of infertility, A history of liver problems and a history of allergy to clomiphene, Percentage of typical forms<4%, Ejaculated volume <1.5 ml, Abnormal serum levels of free testosterone, Prolactin, Luteinizing hormone, Follicle-stimulating hormone

Intervention group:They receive FamiLact capsules once a day for 4 weeks. Control group: They receive placebo once a day for 4 weeks.

Sperm concentration; sperm motility; sperm morphology; semen fluid volume

Patients are randomly divided into two groups of recipients of femoral lactate or placebo capsules using Random Allocation software using reciprocating blocks.

All stages will be covered by the patient, physician, and evaluator. The first presenter identifies the sequence of assignment of patients according to the order of entry of the patients to the study and places the drugs in a uniform envelope and identifies them with A or B codes. He then identifies the medications that are appropriate for each individual according to the above description and puts them in special envelopes and delivers them to patients.